4.6 Review

Chemoradiotherapy Versus Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: A Systemic Review and Meta-analysis of 2138 Patients

Journal

JOURNAL OF CANCER
Volume 8, Issue 2, Pages 287-297

Publisher

IVYSPRING INT PUBL
DOI: 10.7150/jca.17317

Keywords

nasopharyngeal carcinoma; stage II; chemoradiotherapy; radiotherapy; intensity-modulated radiotherapy; meta-analysis

Categories

Funding

  1. National Science & Technology Pillar Program [2014BAI09B10]
  2. Health & Medical Collaborative Innovation Project of Guangzhou City, China [201400000001]
  3. Planned Science and Technology Project of Guangdong Province [2013B020400004]
  4. Science and Technology Project of Guangzhou City, China [14570006]

Ask authors/readers for more resources

Background: To explore the value of chemoradiotherapy (CRT) in stage II nasopharyngeal carcinoma (NPC) compared to radiotherapy (RT) alone which includes two-dimensional radiotherapy (2D-RT) and intensity-modulated radiotherapy (IMRT). Methods: All topic-related comparative articles were identified by a comprehensive search of public databases (MEDLINE, EMBASE, Cochrane Library and CBMdisc). The primary outcomes were overall survival (OS), loco-regional relapse-free survival (LRRFS) and distant metastasis-free survival (DMFS). Secondary outcomes were grade 3-4 acute toxicity events. We performed subgroup analysis of CRT versus 2D-RT/IMRT alone to investigate the optimal modality. Sensitivity analysis focused on CRT versus IMRT alone was used to assess stability of the study results. Results: Eleven comparative studies (2138 patients) were eligible. CRT had significantly higher OS (HR = 0.67, 95% CI = 0.45-0.98, P = 0.04) and LRRFS (HR = 0.61, 95% CI = 0.46-0.80, P = 0.0003) than RT alone, but no significant difference was observed in DMFS (HR = 0.83, 95% CI = 0.52-1.31, P = 0.41). Meanwhile, CRT was associated with higher frequencies of grade 3-4 leukopenia, mucositis and nausea (P = 0.005, 0.03, < 0.0001, respectively). Subgroup analysis showed that IMRT alone could achieve equivalent OS, LRRFS and DMFS compared to CRT (P = 0.14, 0.06, 0.89, respectively). Significant value was only observed in LRRFS for CRT compared to 2D-RT alone (P = 0.01). Sensitivity analysis for the comparison of CRT and IMRT alone demonstrated generally stable outcomes, in support of the final conclusions. Conclusions: In the treatment of patients with stage II NPC, CRT was better than 2D-RT alone with significant benefit in LRRFS. IMRT alone was superior to CRT with equivalent survival outcomes and fewer grade 3-4 acute toxicities.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy

Y. -P. Chen, Y. -Q. Wang, J. -W. Lv, Y. -Q. Li, M. L. K. Chua, Q. -T. Le, N. Lee, A. Dimitrios Colevas, T. Seiwert, D. N. Hayes, N. Riaz, J. B. Vermorken, B. O'Sullivan, Q. -M. He, X. -J. Yang, L. -L. Tang, Y. -P. Mao, Y. Sun, N. Liu, J. Ma

ANNALS OF ONCOLOGY (2019)

Article Endocrinology & Metabolism

Pan-cancer genomic analyses reveal prognostic and immunogenic features of the tumor melatonergic microenvironment across 14 solid cancer types

Jia-Wei Lv, Zi-Qi Zheng, Zi-Xian Wang, Guan-Qun Zhou, Lei Chen, Yan-Ping Mao, Ai-Hua Lin, Russel J. Reiter, Jun Ma, Yu-Pei Chen, Ying Sun

JOURNAL OF PINEAL RESEARCH (2019)

Article Oncology

Effect of prior cancer on trial eligibility and treatment outcomes in nasopharyngeal carcinoma: Implications for clinical trial accrual

Ya-Qin Wang, Jia-Wei Lv, Ling-Long Tang, Xiao-Jing Du, Lei Chen, Wen-Fei Li, Xu Liu, Ying Guo, Ai-Hua Lin, Yan-Ping Mao, Ying Sun, Yu-Pei Chen, Jun Ma

ORAL ONCOLOGY (2019)

Article Oncology

Optimizing the cumulative cisplatin dose during radiotherapy in nasopharyngeal carcinoma: Dose-effect analysis for a large cohort

Liang Peng, Cheng Xu, Yu-Pei Chen, Rui Guo, Yan-Ping Mao, Ying Sun, Jun Ma, Ling-Long Tang

ORAL ONCOLOGY (2019)

Review Radiology, Nuclear Medicine & Medical Imaging

The next decade of clinical trials in locoregionally advanced nasopharyngeal carcinoma

Liang Peng, Jin-Qi Liu, Yu-Pei Chen, Jun Ma

BRITISH JOURNAL OF RADIOLOGY (2019)

Meeting Abstract Oncology

Longitudinal circulating Epstein-Barr virus DNA response to induction chemotherapy and chemo-radiotherapy to identify biological phenotypes in EBV-associated nasopharynx of head and neck cancer.

Jia-Wei Lv, Ying Sun, Yu-Pei Chen, Guan-Qun Zhou, Kuan Rui Lloyd Tan, Jun Ma, Melvin L. K. Chua

JOURNAL OF CLINICAL ONCOLOGY (2019)

Letter Oncology

Identification of cross-talk between m6A and 5mC regulators associated with onco-immunogenic features and prognosis across 33 cancer types

Yu-Tong Chen, Jia-Yi Shen, Dong-Ping Chen, Chen-Fei Wu, Rui Guo, Pan-Pan Zhang, Jia-Wei Lv, Wen-Fei Li, Zi-Xian Wang, Yu-Pei Chen

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Article Cell Biology

Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma

Yu-Pei Chen, Jian-Hua Yin, Wen-Fei Li, Han-Jie Li, Dong-Ping Chen, Cui-Juan Zhang, Jia-Wei Lv, Ya-Qin Wang, Xiao-Min Li, Jun-Yan Li, Pan-Pan Zhang, Ying-Qin Li, Qing-Mei He, Xiao-Jing Yang, Yuan Lei, Ling-Long Tang, Guan-Qun Zhou, Yan-Ping Mao, Chen Wei, Ke-Xu Xiong, Hong-Bo Zhang, Shi-Da Zhu, Yong Hou, Ying Sun, Michael Dean, Ido Amit, Kui Wu, Dong-Ming Kuang, Gui-Bo Li, Na Liu, Jun Ma

CELL RESEARCH (2020)

Article Oncology

Prognostic value of immune score in nasopharyngeal carcinoma using digital pathology

Ya-Qin Wang, Lei Chen, Yan-Ping Mao, Ying-Qing Li, Wei Jiang, Shuo-Yu Xu, Yu Zhang, Yu-Pei Chen, Xiao-Min Li, Qing-Mei He, Shi-Wei He, Xiao-Jing Yang, Yuan Lei, Yin Zhao, Jing-Ping Yun, Na Liu, Yingqin Li, Jun Ma

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Article Oncology

ZNF582hypermethylation promotes metastasis of nasopharyngeal carcinoma by regulating the transcription of adhesion moleculesNectin-3andNRXN3

Yin Zhao, Xiao-Hong Hong, Kang Li, Ying-Qing Li, Ying-Qin Li, Shi-Wei He, Pan-Pan Zhang, Jun-Yan Li, Qian Li, Ye-Lin Liang, Yang Chen, Jun Ma, Na Liu, Yu-Pei Chen

CANCER COMMUNICATIONS (2020)

Article Oncology

Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Yu-Pei Chen, Nofisat Ismaila, Melvin L. K. Chua, A. Dimitrios Colevas, Robert Haddad, Shao Hui Huang, Joseph T. S. Wee, Alexander C. Whitley, Jun-Lin Yi, Sue S. Yom, Anthony T. C. Chan, Chao-Su Hu, Jin-Yi Lang, Quynh-Thu Le, Anne W. M. Lee, Nancy Lee, Jin-Ching Lin, Brigette Ma, Thomas J. Morgan, Jatin Shah, Ying Sun, Jun Ma

Summary: This joint guideline provides evidence-based recommendations for definitive-intent chemoradiotherapy for patients with stage II-IVA nasopharyngeal carcinoma, addressing various aspects of care such as radiotherapy, chemotherapy sequence, and concurrent, induction, and adjuvant chemotherapy options.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Biochemistry & Molecular Biology

Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses

Yu-Pei Chen, Jia-Wei Lv, Yan-Ping Mao, Xiao-Min Li, Jun-Yan Li, Ya-Qin Wang, Cheng Xu, Ying-Qin Li, Qing-Mei He, Xiao-Jing Yang, Yuan Lei, Jia-Yi Shen, Ling-Long Tang, Lei Chen, Guan-Qun Zhou, Wen-Fei Li, Xiao-Jing Du, Rui Guo, Xu Liu, Yuan Zhang, Jing Zeng, Jing-Ping Yun, Ying Sun, Na Liu, Jun Ma

Summary: This study identified immune-enriched and non-immune subtypes in nasopharyngeal carcinoma patients, as well as tumor immune evasion and active immune subtypes within the immune-enriched group. The active immune subtype predicted favorable survival and improved immune checkpoint inhibitor response compared to the immune evasion subtype.

MOLECULAR CANCER (2021)

Article Medicine, General & Internal

Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial

Yu-Pei Chen, Xu Liu, Qin Zhou, Kun-Yu Yang, Feng Jin, Xiao-Dong Zhu, Mei Shi, Guo-Qing Hu, Wei-Han Hu, Yan Sun, Hong-Fen Wu, Hui Wu, Qin Lin, Hui Wang, Ye Tian, Ning Zhang, Xi-Cheng Wang, Liang-Fang Shen, Zheng-Zheng Liu, Jing Huang, Xiu-Ling Luo, Ling Li, Jian Zang, Qi Mei, Bao-Min Zheng, Dan Yue, Jing Xu, San-Gang Wu, Yan-Xia Shi, Yan-Ping Mao, Lei Chen, Wen-Fei Li, Guan-Qun Zhou, Rui Sun, Rui Guo, Yuan Zhang, Cheng Xu, Jia-Wei Lv, Ying Guo, Hui-Xia Feng, Ling-Long Tang, Fang-Yun Xie, Ying Sun, Jun Ma

Summary: This study found that adding oral metronomic capecitabine as adjuvant chemotherapy significantly improved failure-free survival in patients with high-risk locoregionally advanced nasopharyngeal carcinoma, with a good safety profile. These results support the potential role of metronomic chemotherapy as an adjuvant therapy in the treatment of nasopharyngeal carcinoma.

LANCET (2021)

Meeting Abstract Oncology

Effect of Prior Cancer on Trial Eligibility and Treatment Outcomes in Nasopharyngeal Carcinoma: Implications for Clinical Trial Accrual

Ya-Qin Wang, Jia-Wei Lv, Ling-Long Tang, Xiao-Jing Du, Lei Chem, Wen-Fei Li, Xu Liu, Ying Guo, Ai-Hua Lin, Yan-Ping Mao, Ying Sun, Yu-Pei Chen, Jun Ma

CANCER RESEARCH (2019)

No Data Available